Vardy Emma R L C, Hussain Ishrut, Hooper Nigel M
University of Leeds, Academic Unit of Molecular Vascular Medicine, Leeds Institute of Genetics, Health and Therapeutics, Clarendon Way, Leeds LS2 9JT, UK.
Expert Rev Neurother. 2006 May;6(5):695-704. doi: 10.1586/14737175.6.5.695.
Alzheimer's disease (AD) is the most common form of dementia, with prevalence and the accompanying socioeconomic impact set to increase over the coming decades. Currently available medications result, at best, in modest cognitive improvement. With increasing understanding of the underlying pathology, new therapeutic targets are being identified at an ever-increasing rate. The key pathological events in the AD brain are deposition of insoluble amyloid-beta peptide (Abeta), formation of neurofibrillary tangles and neuroinflammation leading, ultimately, to neuronal cell death. Each of these will be considered, in detail, in terms of the variety of therapeutic approaches currently being investigated and mechanisms that may prove amenable to intervention in the future.
阿尔茨海默病（AD）是最常见的痴呆形式，在未来几十年中，其患病率及随之而来的社会经济影响预计将会增加。目前可用的药物充其量只能带来适度的认知改善。随着对潜在病理学的认识不断加深，新的治疗靶点正以越来越快的速度被发现。AD大脑中的关键病理事件是不溶性β淀粉样肽（Aβ）的沉积、神经原纤维缠结的形成以及神经炎症，最终导致神经元细胞死亡。将详细探讨针对这些病理事件的各种当前正在研究的治疗方法以及未来可能适合干预的机制。
